Madrid
,
Spain
9 - 13 September 2024
60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Presentation schedule and materials
The congress symposium is no longer available
Tuesday, 10 September 2024
ORAL PRESENTATION
No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin in T1D: ONWARDS 6
Harald Sourij1; Richard Bracken2; Lisbeth Carstensen3; Thaís M P Rocha3; Sara Kehlet Watt3; Athena Philis-Tsimikas4
ORAL PRESENTATION
Associations between mean fasting glucose levels and adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive type 2 diabetes: post hoc analysis of ONWARDS 5
Harpreet S Bajaj1; Lars V Bennedsen2; Anders M Donatsky2; Johannes H J Martiny2; André Vianna3; Ildiko Lingvay4
MATERIALS AVAILABLE
ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline sodium-glucose cotransporter-2 inhibitor use: ONWARDS 1–5
Ronald Goldenberg1; Ariel Fu2; Monika Kellerer3; Bharath Kumar4; Stinne Byrholdt Søgaard2; Tina Vilsbøll5,6
ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1–5
Tina Vilsbøll1,2; Ariel Fu3; Monika Kellerer4; Bharath Kumar5; Stinne Byrholdt Søgaard3; Ronald Goldenberg6
SHORT ORAL PRESENTATION
Impact of age on the efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily insulin in T2D (ONWARDS 1–5)
André Vianna1; Julie Krogsdahl Bache2; Cyrus Desouza3; Mariana Fragão Marques2; Andrea Navarria2; Shehla Shaikh4; Ildiko Lingvay5
SHORT ORAL PRESENTATION
No evidence of increased physical activity-attributed hypoglycaemia with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes: ONWARDS 1–5
Michael C Riddell1; Simon Heller2; Lisbeth Carstensen3; Thaís M P Rocha3; Sara Kehlet Watt3; Vincent C Woo4
SHORT ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in T2D by ethnicity and race: ONWARDS 1–5
Ildiko Lingvay1; Julie Krogsdahl Bache2; Cyrus Desouza3; Mariana Fragão Marques2; Andrea Navarria2; André Vianna4
SHORT ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1–5
Alice YY Cheng1; Peter Rossing2; Malik Benamar3; Christian Laugesen3; Bharath Kumar4; Harpreet S Bajaj5
SHORT ORAL PRESENTATION
No clinically relevant QTc prolongation with cagrilintide: a thorough QT study in healthy participants
Maria B N Gabe1; Rainard Fuhr2; Angela Sinn2; Astrid Eliasen1; Kasper K Berthelsen1; Anja B Kuhlman1; Tine A Bækdal1; Ayna B Nejad1
MATERIALS AVAILABLE
Wednesday, 11 September 2024
ORAL PRESENTATION
CagriSema-driven weight loss in diet-induced obese rats depends on counter-regulation of weight loss-associated reduction in energy expenditure
Rune Ehrenreich Kuhre1; Julie Mie Jacobsen1; Bjørn Hald1; Johannes Josef Fels1; Ida Blom1,2; Jens Halling1,2; Steen Larsen2; Sofia Lundh1; Marina Kjærgaard Gerstenberg1; Anna Secher1; Kirsten Raun1
MATERIALS AVAILABLE
ORAL PRESENTATION
Safety, tolerability and weight reduction findings of oral amycretin: A novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
Agnes Gasiorek1; Arne Heydorn2; Katrine Kirkeby3; Cassandra Key4; Søren Toubro2; Line Hollesen Schefe1; Kirsten Dahl1; Julie B. Hjerpsted1; Andreas Vegge2
MATERIALS AVAILABLE
ORAL PRESENTATION
CagriSema improves insulin sensitivity in diet-induced obese rats
Anna Secher1; Christian Lehn Brand1; Kirsten Raun1
MATERIALS AVAILABLE
ORAL PRESENTATION
Liraglutide 3.0 mg for the treatment of obesity in children aged 6 to <12 years: results from the first randomised, phase 3 study
Claudia K. Fox1; Margarita Barrientos-Pérez2; Eric M. Bomberg3; John Dcruz4; Inge Gies5; Nina M. Harder-Lauridsen6; Muhammad Yazid Jalaludin7; Kushal Sahu4; Petra Weimers6; Thomas Zueger8,9; Silva Arslanian10
MATERIALS AVAILABLE
Thursday, 12 September 2024
ORAL PRESENTATION
Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A prespecified analysis from the SELECT trial
Helen M. Colhoun1; Steven E. Kahn2; Paul M. Brown3; Emma T. B. Olesen3; Rafael Bravo3; John Deanfield4; Assen Goudev5; Gustavs Latkovskis6; Michael Lehrke7; A. Michael Lincoff8; Naveen Rathor3; Chau-Chung Wu9; Ildiko Lingvay10; On behalf of the SELECT investigator group
MATERIALS AVAILABLE
SHORT ORAL PRESENTATION
Clinical implications of intentional weight loss in people living with T2D: A CPRD Aurum database study
Christian Kruse1; Uffe C Braae1; Emil Nørtoft2; Peter N Kristensen3; Nick F Nielsen4
MATERIALS AVAILABLE
Friday, 13 September 2024
ORAL PRESENTATION
Improvement in time in range after connected insulin pen initiation in Austria
Yvonne Winhofer1; Niels V Hartvig2; Anne Kaas2; Rok Kosmina2; Julia K Mader3
MATERIALS AVAILABLE
ORAL PRESENTATION
Multinational analysis of factors associated with missed bolus insulin injections using connected insulin pen data
F Javier Ampudia-Blasco1,2; Maika Lindkvist Jensen3; Anne Kaas3; Rok Kosmina3; Rimei Nishimura4
MATERIALS AVAILABLE
Keywords